| Ytd | -30.79% | |
| 1y | 103.03% |
| Open | 3.31 | Prev Close | 2.94 | Low | 3.27 | High | 3.39 | Mkt Cap | 337.05M |
| Vol | 23.40K | Avg Vol | 38.71K | EPS | -0.67 | P/E | N/A | Forward P/E | -2.07 |
| Beta | 3.20 | Short Ratio | 1.41 | Inst. Own | 16.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 3.48 | 200-d Avg | 3.82 | 1yr Est | 6.67 |
CLLS News
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDA
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASD
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pi
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASD
PARIS, June 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Dat
Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ:CLLS) with a Overweight ra
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pi
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDA
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.16) per share which beat the analyst consen
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pi
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NAS
Citizens analyst Silvan Turkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and m
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS -
NEW YORK, 13 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), société
Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to d
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NAS
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASD
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of
Shares of Cellectis S.A. (NASDAQ: CLLS - Get Free Report) passed below its 50 day moving average dur
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of
Clear Street analyst Bill Maughan initiates coverage on Cellectis (NASDAQ:CLLS) with a Buy rating
Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev
Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of
Cellectis reports strong Nature Communications data showing CssDNA boosts non-viral gene insertion e
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pi
Cellectis (NASDAQ:CLLS) reported quarterly earnings of $0.02 per share which beat the analyst consen
Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and raises the pri
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday'
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Mo